In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection

COVID-19 has currently become the biggest challenge in the world. There is still no specific medicine for COVID-19, which leaves a critical gap for the identification of new drug candidates for the disease. Recent studies have reported that the small-molecule enoxacin exerts an antiviral activity by enhancing the RNAi pathway. The aim of this study is to analyze if enoxacin can exert anti-SARS-CoV-2 effects. We exploit multiple computational tools and databases to examine (i) whether the RNAi mechanism, as the target pathway of enoxacin, could act on the SARS-CoV-2 genome, and (ii) microRNAs induced by enoxacin might directly silence viral components as well as the host cell proteins mediating the viral entry and replication. We find that the RNA genome of SARS-CoV-2 might be a suitable substrate for DICER activity. We also highlight several enoxacin-enhanced microRNAs which could target SARS-CoV-2 components, pro-inflammatory cytokines, host cell components facilitating viral replication, and transcription factors enriched in lung stem cells, thereby promoting their differentiation and lung regeneration. Finally, our analyses identify several enoxacin-targeted regulatory modules that were critically associated with exacerbation of the SARS-CoV-2 infection. Overall, our analysis suggests that enoxacin could be a promising candidate for COVID-19 treatment through enhancing the RNAi pathway.

Abstract licence: CC BY-NC-ND

1. 17.

   Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool · 2013

2. 26.

   cytoHubba: identifying hub objects and sub-networks from complex interactome · 2014

3. 28.

   miRDB: an online resource for microRNA target prediction and functional annotations · 2014

4. 30.

   Predicting effective microRNA target sites in mammalian mRNAs · 2015

5. 39.

   ComiR: combinatorial microRNA target prediction tool · 2013

6. 40.

   miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database · 2015

7. 55.

   Anti-Inflammatory MicroRNAs and Their Potential for Inflammatory Diseases Treatment · 2018

8. 56.

   Cytokine release syndrome · 2018

9. 67.

   Let ‐ 7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer · 2019

10. 68.

    miRDB: an online database for prediction of functional microRNA targets · 2019

11. 72.

    MIENTURNET: an interactive web tool for microRNA-target enrichment and network-based analysis · 2019

12. 79.

    Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 · 2020

13. 80.

    COVID-19: a new challenge for human beings · 2020

14. 92.

    Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing · 2020

15. 95.

    A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 · 2020

16. 96.

    Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection · 2020

17. 101.

    SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy · 2020

18. 102.

    Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies · 2020

19. 108.

    Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies · 2020

20. 112.

    How COVID-19 induces cytokine storm with high mortality · 2020

21. 114.

    miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19 · 2020

22. 121.

    SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself · 2021

103 more references, whose wording the paper’s licence keeps private.

• SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence · 2023

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.